IDH1 and astrocytoma (excluding glioblastoma): Patients included in the NOA16 trial were diagnosed with either WHO grade 3 or 4 astrocytomas, leaving the door open for IDH vaccination research in patients affected by oligodendroglioma to understand whether IDH vaccination can benefit this group.